TITLE

Expression of manganese superoxide dismutase in esophageal and gastric cancers

AUTHOR(S)
Izutani, Ryo; Asano, Satoshi; Imano, Motohiro; Kuroda, Daisuke; Kato, Michio; Ohyanagi, Harumasa; Izutani, R; Asano, S; Imano, M; Kuroda, D; Kato, M; Ohyanagi, H
PUB. DATE
December 1998
SOURCE
Journal of Gastroenterology;1998, Vol. 33 Issue 6, p816
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
The tumor-killing activity of radiotherapy and chemotherapy for cancer is closely associated with the production of active oxygen, and the relation between therapeutic resistance and active oxygen scavengers produced by the tumor itself is gaining more attention. It is considered that manganese superoxide dismutase (MnSOD) protects host cells from oxidative stress, in synergy with other antioxidant enzymes. In this study, we used a quantitative polymerase chain reaction assay to measure MnSOD mRNA in resected specimens from patients with esophageal and gastric cancers. In both esophageal and gastric cancers, the level of MnSOD mRNA was significantly elevated in cancer tissue compared to non-cancer tissue (P < 0.01). In gastric cancer tissue, the MnSOD mRNA level was significantly higher than in esophageal cancer tissue (P < 0.01). The significance of MnSOD in cancer tissue was investigated further by measuring MnSOD content in resected specimens using an enzyme-linked immunosorbent assay, and by examining its location by an immunohistochemical method. Upregulation of MnSOD in cancer tissue most likely serves as a protective mechanism against anti-cancer therapies known to produce superoxide radicals as a key component of their tumor-killing activity.
ACCESSION #
4690003

 

Related Articles

  • Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Posner, M. R.; Lorch, J. H.; Goloubeva, O.; Tan, M.; Schumaker, L. M.; Sarlis, N. J.; Haddad, R. I.; Cullen, K. J. // Annals of Oncology;May2011, Vol. 22 Issue 5, p1071 

    Background: The association between human papillomavirus (HPV) and overall survival (OS) in oropharynx cancer (OPC) was retrospectively examined in TAX 324, a phase III trial of sequential therapy for locally advanced head and neck cancer.Methods: Accrual for TAX 324 was completed in 2003 and...

  • Alternating Chemotherapy and Radiotherapy in Locally Advanced Head and Neck Cancer: An Alternative? Marco Merlano // Oncologist;Feb2006, Vol. 11 Issue 2, p146 

    Rapidly alternating chemotherapy and radiotherapy (ACR) is a minor variation of concurrent chemoradiation (CCR). This scheduling has been tested in advanced head and neck cancer and has shown superiority over standard radiation in some randomized trials with only marginally greater toxicity....

  • Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Ichikawa, W.; Takahashi, T.; Suto, K.; Yamashita, T.; Nihei, Z.; Shirota, Y.; Shimizu, M.; Sasaki, Y.; Hirayama, R. // British Journal of Cancer;10/04/2004, Vol. 91 Issue 7, p1245 

    The predictive values of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) gene expressions were retrospectively evaluated in patients with gastric cancer treated by a regimen containing S-I. The study population consisted of 53 patients registered into different two phase II...

  • Detection of disseminated tumor cells in the lymph nodes of colorectal cancer patients using a real-time polymerase chain reaction assay. Lotspeich, Erkki; Schoene, Markus; Gerngroß, Heinz; Schmidt, Roland; Steinmann, Reinhard; Ramadani, Marco; Gansauge, Susanne // Langenbeck's Archives of Surgery;Oct2007, Vol. 392 Issue 5, p559 

    Postoperative treatment for colorectal cancer depends on tumor stage as defined by the International Union Against Cancer (UICC). Adjuvant chemotherapy is not recommended in patients without lymph node involvement (UICC stages I and II). As many as 20–30% of these patients, however, will...

  • Low- to high-throughput analysis of telomerase modulators with Telospot. Cristofari, Gaël; Reichenbach, Patrick; Regamey, Pierre-Olivier; Banfi, Damiano; Chambon, Marc; Turcatti, Gerardo; Lingner, Joachim // Nature Methods;Oct2007, Vol. 4 Issue 10, p851 

    We designed a method termed Telospot to discover and characterize telomerase modulators as anticancer drugs or chemical biology tools. Telospot is based on a highly efficient human telomerase expression system and the detection of telomerase DNA reaction products in macroarray format. Telospot...

  • Gene assay to help to predict lung cancer treatment resistance.  // Medical Device Daily;11/1/2009, p2 

    The article describes a study which examined the correlation between genes believed to be involved in drug sensitivity and resistance and actual in vitro chemosensitivity for non-small cell lung cancer (NSCLC). Researcher Ian Cree and colleagues assess the chemosensitivity of a series of 49...

  • Glutathione- S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients. Ott, Katja; Lordick, Florian; Becker, Karen; Ulm, Kurt; Siewert, JörgRüdiger; Höfler, Heinz; Keller, Gisela // International Journal of Colorectal Disease;Aug2008, Vol. 23 Issue 8, p773 

    Neoadjuvant chemotherapy in gastric cancer is now standard in the Western world; however, only 30–40% of the patients respond to induction therapy. Pretherapeutic predictors of response and prognosis would be of utmost interest to individualize treatment. Glutathione- S-transferase...

  • In Vivo Imaging, Tracking, and Targeting of Cancer Stem Cells. Viashi, Erina; Kwanghee Kim; Lagadec, Chann; Donna, Lorenza Della; McDonald, John Tyson; Eghbali, Mansoureh; Sayre, James W.; Stefani, Encrico; McBride, William; Pajonk, Frank // JNCI: Journal of the National Cancer Institute;3/4/2009, Vol. 101 Issue 5, p350 

    Background There is increasing evidence that solid cancers contain cancer-initiating cells (CICs) that are capable of regenerating a tumor that has been surgically removed and/or treated with chemotherapy and/or radiation therapy. Currently, cell surface markers, like CD133 or CD44, are used to...

  • Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Gronchi, A.; Bui, B. N.; Bonvalot, S.; Pilotti, S.; Ferrari, S.; Hohenberger, P.; Hohl, R. J.; Demetri, G. D.; Le Cesne, A.; Lardelli, P.; Pérez, I.; Nieto, A.; Tercero, J. C.; Alfaro, V.; Tamborini, E.; Blay, J. Y. // Annals of Oncology;Mar2012, Vol. 23 Issue 3, p771 

    Background: To evaluate neoadjuvant trabectedin (1.5 mg/m2 24-h i.v. infusion every 3 weeks; three to six cycles) in patients with locally advanced myoxid liposarcoma (ML) previously untreated with chemotherapy or radiation. Patients and methods: Primary efficacy end point was pathological...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics